Atogepant, marketed as Qulipta, is a medication approved for the preventive treatment of episodic migraine in adults [1]. It belongs to a class of drugs known as CGRP inhibitors [2].
How does Atogepant work for migraine prevention?
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a molecule that plays a role in migraine pathophysiology. By blocking the CGRP receptor, atogepant is thought to inhibit the activity of CGRP, thereby helping to prevent migraine attacks [1][2].
What is the difference between Qulipta and other migraine treatments?
Unlike some other migraine preventive medications that were originally developed for different conditions, Qulipta was specifically developed as a CGRP inhibitor for migraine prevention [2]. Traditional preventive medications can include beta-blockers, antidepressants, and anticonvulsants, which have different mechanisms of action and potential side effect profiles [3]. Qulipta offers a targeted approach to migraine prevention by focusing on the CGRP pathway [1][2].
What are the approved uses for Qulipta?
Qulipta is approved for the preventive treatment of episodic migraine in adults who have had at least four migraine days per month in the previous three months [1]. It is not intended for the acute treatment of migraine attacks [4].
What are the potential side effects of Atogepant?
Common side effects of atogepant include constipation, nausea, and fatigue [1]. It is important to discuss any concerns about side effects with a healthcare provider [5].
When does the patent for Qulipta expire?
Information on specific patent expiry dates for Qulipta can be found on specialized pharmaceutical patent databases [6]. DrugPatentWatch.com provides comprehensive data on drug patents and their expiration timelines [6].
Can generic versions of Atogepant be made?
The availability of generic versions of atogepant, also known as atogepant, depends on patent expiry and any associated market exclusivity periods. Once patents expire and regulatory hurdles are cleared, generic manufacturers may be able to produce and market their versions of the drug [6].